Modulation of the gut microbiota represents a new management for non-alcoholic fatty liver disease.
作者信息
Bakhshimoghaddam Farnush, Alizadeh Mohammad
机构信息
Student Research Committee, Department of Nutrition, Food and Beverages Safety Research Center, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Department of Nutrition, Food and Beverages Safety Research Center, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
出版信息
Hepatobiliary Surg Nutr. 2020 Apr;9(2):223-226. doi: 10.21037/hbsn.2019.10.01.
Abstract
摘要
相似文献
1
Modulation of the gut microbiota represents a new management for non-alcoholic fatty liver disease.肠道微生物群的调节代表了非酒精性脂肪性肝病的一种新的治疗方法。
Hepatobiliary Surg Nutr. 2020 Apr;9(2):223-226. doi: 10.21037/hbsn.2019.10.01.
2
Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice.肠道微生物群移植、槲皮素与高脂饮食之间的功能相互作用决定无菌小鼠非酒精性脂肪性肝病的发生。
Mol Nutr Food Res. 2019 Apr;63(8):e1800930. doi: 10.1002/mnfr.201800930. Epub 2019 Feb 4.
3
Review article: Alcohol and gut microbiota - the possible role of gut microbiota modulation in the treatment of alcoholic liver disease.综述文章：酒精与肠道微生物群——肠道微生物群调节在酒精性肝病治疗中的可能作用
Aliment Pharmacol Ther. 2015 May;41(10):917-27. doi: 10.1111/apt.13164. Epub 2015 Mar 23.
4
Nonalcoholic Fatty Liver Disease and the Gut Microbiome.非酒精性脂肪性肝病与肠道微生物组。
Clin Liver Dis. 2016 May;20(2):263-75. doi: 10.1016/j.cld.2015.10.012. Epub 2015 Dec 24.
5
New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.肠道微生物群在非酒精性脂肪性肝病及其相关肝癌中的新见解和治疗意义。
Cancer Lett. 2019 Sep 10;459:186-191. doi: 10.1016/j.canlet.2019.114425. Epub 2019 Jun 8.
6
Alcohol, liver disease and the gut microbiota.酒精、肝病与肠道微生物组。
Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):235-246. doi: 10.1038/s41575-018-0099-1.
7
Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies.肠-肝轴与非酒精性脂肪性肝病纤维化：新型治疗方法的切入点。
Dig Liver Dis. 2013 Jul;45(7):543-51. doi: 10.1016/j.dld.2012.11.010. Epub 2012 Dec 29.
8
Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.靶向肠道微生物组治疗非酒精性脂肪性肝病的机制和治疗进展。
Front Med. 2018 Dec;12(6):645-657. doi: 10.1007/s11684-018-0645-9. Epub 2018 Sep 4.
9
Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats.用绞股蓝缓解大鼠非酒精性脂肪肝病过程中肠道微生物群的结构调节。
BMC Complement Med Ther. 2020 Feb 5;20(1):34. doi: 10.1186/s12906-020-2835-7.
10
Gut microbiota, fatty liver disease, and hepatocellular carcinoma.肠道微生物群、脂肪性肝病和肝细胞癌
Liver Res. 2018 Mar;2(1):43-51. doi: 10.1016/j.livres.2017.11.005. Epub 2018 Feb 21.
引用本文的文献
1
The Gut Microbiome Responds Progressively to Fat and/or Sugar-Rich Diets and Is Differentially Modified by Dietary Fat and Sugar.肠道微生物组对高脂肪和/或高糖饮食逐渐做出反应，并且饮食中的脂肪和糖对其有不同的影响。
Nutrients. 2023 Apr 27;15(9):2097. doi: 10.3390/nu15092097.
2
The Role of the Gut Microbiome in Liver Cirrhosis Treatment.肠道微生物群在肝硬化治疗中的作用。
Int J Mol Sci. 2020 Dec 28;22(1):199. doi: 10.3390/ijms22010199.
本文引用的文献
1
Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.非酒精性脂肪性肝病的肠道微生物组靶向治疗：系统评价、荟萃分析和荟萃回归。
Am J Clin Nutr. 2019 Jul 1;110(1):139-149. doi: 10.1093/ajcn/nqz042.
2
Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial.每日食用合生素酸奶可减少非酒精性脂肪肝患者的肝脂肪变性：一项随机对照临床试验。
J Nutr. 2018 Aug 1;148(8):1276-1284. doi: 10.1093/jn/nxy088.
3
Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis.益生菌和合生菌摄入对肝功能试验酶血清浓度的影响：系统评价和荟萃分析。
Eur J Nutr. 2018 Sep;57(6):2037-2053. doi: 10.1007/s00394-017-1568-y. Epub 2017 Nov 8.
4
Role of nutrition, gene polymorphism, and gut microbiota in non-alcoholic fatty liver disease.营养、基因多态性和肠道微生物群在非酒精性脂肪性肝病中的作用。
Discov Med. 2017 Sep;24(131):95-106.
5
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.非酒精性脂肪性肝病的诊断与管理：美国肝病研究协会的实践指南
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
6
Impact of the gut microbiota on inflammation, obesity, and metabolic disease.肠道微生物群对炎症、肥胖和代谢性疾病的影响。
Genome Med. 2016 Apr 20;8(1):42. doi: 10.1186/s13073-016-0303-2.
7
Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.益生菌对非酒精性脂肪性肝病的影响：一项荟萃分析。
World J Gastroenterol. 2013 Oct 28;19(40):6911-8. doi: 10.3748/wjg.v19.i40.6911.
8
Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology.非酒精性脂肪性肝病及其相关代谢紊乱的诊断和治疗：中国内分泌学会肝脏与代谢学组的共识声明。
J Diabetes. 2013 Dec;5(4):406-15. doi: 10.1111/1753-0407.12056. Epub 2013 Jun 4.
9
VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation.VSL#3 可重置胰岛素信号，防止遗传血脂异常和肠道炎症模型中的 NASH 和动脉粥样硬化。
PLoS One. 2012;7(9):e45425. doi: 10.1371/journal.pone.0045425. Epub 2012 Sep 21.
10
Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD).非酒精性脂肪性肝病（NAFLD）患者的营养、肠道通透性和血乙醇水平发生改变。
Dig Dis Sci. 2012 Jul;57(7):1932-41. doi: 10.1007/s10620-012-2112-9. Epub 2012 Mar 17.
Zotero 插件